Pioneering the development of Precision Antibiotics to combat Antimicrobial Resistance
Glox Therapeutics is developing precision, engineered protein bacteriocins to target drug-resistant pathogenic bacteria
Initially built out of 20+ years of research, Glox Therapeutics has globally recognised expertise in elucidating bacteriocin structure and function and developing bacteriocin-based strategies to prevent and treat bacterial infections. The company is developing a pipeline of engineered precision bacteriocins targeting pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae that cause serious infections associated with high levels of antimicrobial resistance (AMR) and mortality.
The Glox Discovery Platform has been developed from over 20 years of research into precision antimicrobials.
The Glox Development Program targets pathogenic bacteria related to Anti-Microbial Resistance (AMR).